The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1555
September 10, 2018
View Complete Issue         Table of Contents 2019 
Issue 1555
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Roxybond - An Abuse-Deterrent Formulation of Short-Acting Oxycodone
September 10, 2018 (Issue: 1555)
The FDA has approved Roxybond (Daiichi Sankyo), an short-acting (SA) oxycodone formulation with abuse-deterrent properties, for treatment of pain requiring management with an opioid. Roxybond is the first SA opioid to be approved as an...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1555
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.